Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Meignier

Showing results (41-50 of 43) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 43 results.
Virology|May 26, 1997
Challenge of chimpanzees immunized with a recombinant canarypox-HIV-1 virusM Girard, E van der Ryst, F Barré-Sinoussi, et al.
Virology|May 1, 1992
NYVAC: a highly attenuated strain of vaccinia virusJ Tartaglia, M E Perkus, J Taylor, et al.
AIDS Research and Human Retroviruses|May 20, 1999
Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le SidaD Salmon-Céron, J L Excler, L Finkielsztejn, et al.
Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 43 results.
Virology|May 26, 1997
Challenge of chimpanzees immunized with a recombinant canarypox-HIV-1 virusM Girard, E van der Ryst, F Barré-Sinoussi, et al.
Virology|May 1, 1992
NYVAC: a highly attenuated strain of vaccinia virusJ Tartaglia, M E Perkus, J Taylor, et al.
AIDS Research and Human Retroviruses|May 20, 1999
Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le SidaD Salmon-Céron, J L Excler, L Finkielsztejn, et al.
Pageof 5